ASH: High-dose gene transfer beneficial in severe hemophilia A

December 11, 2017

(HealthDay)—For men with severe hemophilia A, high-dose factor VIII gene transfer is associated with sustained normalization of factor VIII activity levels, according to a study published online Dec. 9 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.

Savita Rangarajan, M.B., B.S., from Hampshire Hospitals NHS Foundation Trust in Basingstoke, U.K., and colleagues infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]).

The researchers found that recipients of the low or intermediate dose had factor VIII that remained at 3 IU or less/dL. In all seven participants in the high-dose cohort, the factor VIII activity level was more than 5 IU/dL between weeks two and nine after ; in six participants the level increased to a normal value (>50 IU/dL), which was maintained at one year after receipt.

"The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of one year in six of seven participants who received a ," the authors write.

The study was funded by BioMarin Pharmaceutical.

Explore further: Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

March 31, 2017
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A

December 8, 2017
As a gene therapy cure for hemophilia A moves closer to reality, a new study sheds light on a challenging complication in which a host autoimmune response inhibits the production of normal clotting factor VIII from the transferred ...

New findings offer hope for those with severe hemophilia

May 26, 2016
(HealthDay)—Two new studies could pave the way to major changes in how severe cases of hemophilia are treated. Both studies were published in the May 26 issue of the New England Journal of Medicine.

Third dose of MMR vaccine could help curb mumps outbreaks

September 8, 2017
(HealthDay)—A third dose of the measles-mumps-rubella (MMR) vaccine lowers the risk of mumps during an outbreak, according to a study published online Sept. 6 in the New England Journal of Medicine.

Inhibitor development risk similar for factor VIII products

January 17, 2013
(HealthDay)—For children with severe hemophilia A, the risk of inhibitor development is similar with plasma-derived and recombinant factor VIII products and is not affected by von Willebrand factor content or by switching ...

Recommended for you

A wearable device intervention to increase exercise in peripheral artery disease

April 24, 2018
A home-based exercise program, consisting of wearable devices and telephone coaching, did not improve walking ability for patients with peripheral artery disease, according to a new Northwestern Medicine study.

Heart disease may only be a matter of time for those with healthy obesity

April 24, 2018
People who are 30 pounds or more overweight may want to slim down a bit even if they don't have high blood pressure or any other heart disease risk, according to scientists at Wake Forest Baptist Medical Center.

Women at greater risk of stress-induced ischemia after heart attacks

April 24, 2018
Women who've previously experienced a heart attack have twice the risk of later myocardial ischemia provoked by mental stress when compared to men with a similar history, according to a study published in Circulation.

Electric cars don't jolt implanted heart devices: study

April 24, 2018
(HealthDay)—People who have implanted devices to keep their hearts running smoothly can safely drive an electric car if they wish to do so, new research confirms.

Hippo pathway found essential to orchestrate the development of the heart

April 23, 2018
Using a technology that provides a 'high-resolution view' of the status of individual cells, a team of researchers has gained new insights into the embryonic development of the mouse heart. They discovered that during development, ...

Compound improves stroke outcome by reducing lingering inflammation

April 20, 2018
An experimental compound appears to improve stroke outcome by reducing the destructive inflammation that can continue months after a stroke, scientists report.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.